Exploring Jiuzhitang Co., Ltd. Investor Profile: Who’s Buying and Why?

Curious who's backing Jiuzhitang Co., Ltd. (000989.SZ) and why this TCM name keeps drawing strategic interest? Institutional moves tell the story: in April 2022 Yifeng Pharmacy Chain agreed to buy a 5% stake from Li Zhenguo for CNY 430 million, a deal later terminated in November 2024, while Heilongjiang Chenneng University of Technology Venture Capital still holds a commanding 17.79% as of March 2025 but announced plans to trim up to 1% that same month-actions that align with wider market pressure after a roughly 34.97% decline in market capitalization from December 2015 to November 2025; these shareholder shifts coincide with Jiuzhitang reporting a 19.91% revenue drop in 2024, a net profit margin near 9.1% and a dividend payout of CNY 0.30 per share, so explore the following sections to unpack which investors remain committed, which are stepping back, and what those moves mean for valuation and strategy.

Jiuzhitang Co., Ltd. (000989.SZ) - Who Invests in Jiuzhitang Co., Ltd. and Why?

• Institutional investors predominate: strategic buyers (pharmacy chains, pharma firms) and financial investors (VC/PE, university-affiliated VCs).
• Investment motives: secure supply/brand synergies, expand retail distribution, capture TCM growth, and extract operational/technology improvements.
• Risk considerations prompting reassessments: regulatory shifts in TCM, margin pressure, M&A execution risk, and portfolio rebalancing.

• Strategic buyers (e.g., pharmacy chains) pursue minority stakes to secure supply chains, distribution and cross-selling opportunities.
• Financial institutions/VCs monitor regulatory and margin trends and may trade stakes opportunistically.
• University-affiliated VC (e.g., Heilongjiang Chenneng) demonstrates active portfolio management via modest stake reductions.

Institutional Ownership and Major Shareholders of Jiuzhitang Co., Ltd. (000989.SZ)

Key recent developments in Jiuzhitang Co., Ltd.'s shareholder base indicate active repositioning by strategic and financial investors, with notable movements from industry-related buyers and venture capital interests.

• As of March 2025, Heilongjiang Chenneng University of Technology Venture Capital Co., Ltd. (Chenneng Venture Capital) holds 17.79% of Jiuzhitang, making it the largest disclosed shareholder.
• In April 2022, Yifeng Pharmacy Chain Co., Ltd. agreed to acquire a 5% stake from Li Zhenguo, signaling retail-pharmacy sector interest in Jiuzhitang's business.
• Yifeng Pharmacy terminated the planned acquisition in November 2024, reversing that strategic move and removing the immediate prospect of a 5% retail-sector anchor investor.
• In March 2025, Chenneng Venture Capital announced intentions to reduce its holdings by up to 1% (i.e., a potential decrease from 17.79% toward ~16.79%), reflecting a more cautious stance.

• Investor implications: Chenneng's large holding with a planned small reduction suggests profit-taking or portfolio rebalancing rather than full exit; Yifeng's terminated purchase signals either due diligence concerns or shifting retail-strategy priorities.
• Market-watch items: follow Chenneng's actual sell-through (timing, tranche sizes), any renewed approaches from sector players like Yifeng, and filings that clarify Li Zhenguo's residual stake.
• For deeper background on Jiuzhitang's ownership evolution and strategic context, see: Jiuzhitang Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Jiuzhitang Co., Ltd. (000989.SZ) Key Investors and Their Impact on Jiuzhitang Co., Ltd.

• Chenneng Venture Capital: holding 17.79% of Jiuzhitang's shares as of March 2025, giving it material influence on board-level decisions and strategic direction.
• Yifeng Pharmacy Chain: agreed to acquire 5% in April 2022 but terminated the acquisition in November 2024, signaling a strategic reassessment or concerns about Jiuzhitang's near-term prospects.
• March 2025 announcement: Chenneng Venture Capital plans to reduce its holdings by up to 1%, reflecting a cautious stance and possible portfolio rebalancing.

• Control dynamics: With a 17.79% stake, Chenneng remains the largest identifiable institutional holder, able to influence nominations and strategic votes.
• Strategic partnership risk: Yifeng's aborted entry (5% agreement -> termination) removed a potential distribution/retail partner that could have bolstered channel access.
• Market liquidity and sentiment: Announced staged selling by Chenneng (up to 1%) can increase supply and heighten short-term volatility; the exact market impact depends on execution speed and market depth.
• Signalling: The sequence-Yifeng termination (Nov 2024) followed by Chenneng's partial reduction plan (Mar 2025)-may be interpreted by investors as increased caution among strategic holders.

Jiuzhitang Co., Ltd. (000989.SZ) - Market Impact and Investor Sentiment

• Market capitalization trend: decrease of approximately 34.97% from December 2015 to November 2025, reflecting prolonged negative re-rating pressure.
• Key investor actions: termination of Yifeng Pharmacy Chain's acquisition (Nov 2024) and Chenneng Venture Capital's disclosed intention to reduce holdings by up to 1% (Mar 2025) - signals of cautious insider/major-holder positioning.
• Operational performance: 2024 revenue down 19.91% year-on-year; net profit margin ~9.1% in 2024 supports moderate profitability but weaker top-line momentum.
• Shareholder returns: cash dividend CNY 0.30 per share (recent policy), providing income appeal to yield-focused investors despite earnings pressure.

• Investor sentiment drivers: weak revenue growth, moderate margins, aborted M&A, and partial exits by strategic holders.
• Market reaction dynamics: share-price pressure from strategy uncertainty; dividend provides a stabilizing factor for income-oriented holders.
• Watch factors: renewed strategic partners or acquisition activity, quarterly earnings recovery, and any change in major-holder intentions.